Dashboard
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.67 times
Poor long term growth as Net Sales has grown by an annual rate of 6.27% over the last 5 years
The company declared negative results in Sep'26 after flat results in Jun'26
Stock is technically in a Bullish range
With ROE of 18.7, it has a Fair valuation with a 6.7 Price to Book Value
High Institutional Holdings at 39.18%
Stock DNA
Pharmaceuticals & Biotechnology
INR 74,246 Cr (Mid Cap)
36.00
40
0.10%
0.01
18.75%
6.60
Total Returns (Price + Dividend) 
Latest dividend: 2.5 per share ex-dividend date: Aug-31-2026
Risk Adjusted Returns v/s 
Returns Beta
News

Glenmark Pharmaceuticals Sees Significant Open Interest Surge Amid Bullish Market Positioning
Glenmark Pharmaceuticals Ltd. has witnessed a notable surge in open interest in its derivatives segment, signalling increased market participation and potential directional bets. The stock, trading close to its 52-week high, has outperformed its sector and broader indices, reflecting growing investor confidence amid shifting market dynamics.
Read More
Glenmark Pharmaceuticals Sees Significant Open Interest Surge Amid Bullish Market Positioning
Glenmark Pharmaceuticals Ltd. has witnessed a notable surge in open interest in its derivatives segment, signalling a shift in market sentiment and positioning. The stock’s recent outperformance relative to its sector and the broader Sensex, combined with increased futures and options activity, suggests investors are taking fresh directional bets amid a backdrop of strong technicals and improving fundamentals.
Read More
Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Bullish Market Positioning
Glenmark Pharmaceuticals Ltd. has witnessed a notable surge in open interest in its derivatives segment, signalling increased market participation and potential directional bets. The stock’s recent performance, coupled with rising volumes and improved technical positioning, suggests a cautiously optimistic outlook for this mid-cap pharmaceutical player.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Press Release / Media Release
17-Nov-2026 | Source : BSEIchnos Glenmark Innovation (IGI) announces IND submission to US FDA for ISB 2301
Announcement under Regulation 30 (LODR)-Press Release / Media Release
16-Nov-2026 | Source : BSEGlenmark Pharmaceuticals Inc. USA Launches Authorised Generic of INLYTA (axitinib) Tablets 1 mg and 5mg
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
09-Nov-2026 | Source : BSETranscript of the Earnings Call
Corporate Actions 
No Upcoming Board Meetings
Glenmark Pharmaceuticals Ltd. has declared 250% dividend, ex-date: 31 Aug 26
Glenmark Pharmaceuticals Ltd. has announced 1:2 stock split, ex-date: 10 Sep 07
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 38 Schemes (15.61%)
Held by 394 FIIs (21.51%)
Saldanha Family Trust (45.44%)
Hdfc Mutual Fund - Hdfc Manufacturing Fund (6.01%)
10.44%
Quarterly Results Snapshot (Consolidated) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 5.69% vs 6.57% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is -45.38% vs 60.22% in Jun 2026
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 39.43% vs 6.96% in Sep 2024
Growth in half year ended Sep 2025 is -5.37% vs 921.44% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 31.26% vs 15.03% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 1.73% vs 467.86% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 27.48% vs 12.77% in Mar 2025
YoY Growth in year ended Mar 2026 is 30.06% vs 169.73% in Mar 2025